LENZ Therapeutics (LENZ) investor relations material

Launch progress and product performance

• Product launched in early October, with strong initial uptake and positive real-world feedback from doctors and patients.

• Near vision improvement is rapid (10–15 minutes) and lasts a full workday; some report 11–12 hours of effect.

• Side effects like mild stinging and hyperemia are transient and diminish after a few days; headaches are rare and decrease quickly.

• Both e-pharmacy and retail pharmacy channels are fully operational, with guaranteed fixed pricing and broad accessibility.

• Over 2,500 doctors prescribed in the first four weeks, with 5,000 scripts filled; 40% of doctors wrote more than one script.

Commercial strategy and direct-to-consumer (DTC) plans

• DTC campaign launches in Q1, led by spokesperson Sarah Jessica Parker, targeting urban, 45–55-year-old, predominantly female consumers.

• Digital ads will be highly targeted and fine-tuned across platforms like Instagram, TikTok, Hulu, and Disney.

• Influencers will supplement the campaign, and ad effectiveness will be closely monitored and adjusted in real time.

• DTC expected to drive new patient starts, with refill rates becoming a key metric by Q2–Q3.

• Pricing set at $79/month or $198 for a three-pack, based on extensive consumer research; product is cash pay but requires a prescription.

Market expansion and partnerships

• NDA submitted in South Korea via Lotus partnership; similar agreements in place for Greater China and Canada.

• European registration is being pursued directly to maximize value; ex-US market seen as a major growth opportunity.

• U.S. supply chain is robust, with manufacturing and IP based domestically, and product returns duty-free after European fill-finish.

• Redundancy measures include second-source API and fill-finish capabilities nearing submission.